Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-10
DOI
10.1038/s41598-019-55096-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Physical Exercise on Inflammatory Markers in Type 2 Diabetes Patients: A Systematic Review of Randomized Controlled Trials
- (2017) Luciana Costa Melo et al. Oxidative Medicine and Cellular Longevity
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
- (2017) Zev A. Wainberg et al. Targeted Oncology
- Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
- (2016) Antonis Koussounadis et al. BMC CANCER
- Emerging strategies for targeting PI3K in gynecologic cancer
- (2016) Amy J. Bregar et al. GYNECOLOGIC ONCOLOGY
- Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX
- (2016) Alice Iezzi et al. Translational Oncology
- Genetic and molecular changes in ovarian cancer
- (2016) Robert L Hollis et al. Cancer Biology & Medicine
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
- (2015) Seiji Mabuchi et al. GYNECOLOGIC ONCOLOGY
- The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
- (2015) Bianca Cheaib et al. Chinese Journal of Cancer
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
- (2012) A H Sims et al. BRITISH JOURNAL OF CANCER
- Abstract LB-302: Activity of PF-04691502, A dual PI3K/mTOR inhibitor in breast cancer cell lines and models discriminates between ER, PR and HER2 positive and negative segments
- (2011) Jing Yuan et al. CANCER RESEARCH
- Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies
- (2011) D. Faratian et al. CLINICAL CANCER RESEARCH
- Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy
- (2011) Dana Faratian et al. EUROPEAN JOURNAL OF CANCER
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
- (2010) Hengmiao Cheng et al. MedChemComm
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search